IVERIC bio, Inc.

NasdaqGS:ISEE 주식 보고서

시가총액: US$5.5b

IVERIC bio 관리

관리 기준 확인 3/4

IVERIC bio CEO는 Glenn Sblendorio, Jul2017 에 임명되었습니다 의 임기는 6.17 년입니다. 총 연간 보상은 $ 9.82M, 7.1% 로 구성됩니다. 7.1% 급여 및 92.9% 보너스(회사 주식 및 옵션 포함). 는 $ 9.56M 가치에 해당하는 회사 주식의 0.17% 직접 소유합니다. 9.56M. 경영진과 이사회의 평균 재임 기간은 각각 5.5 년과 4.6 년입니다.

주요 정보

Glenn Sblendorio

최고 경영자

US$9.8m

총 보상

CEO 급여 비율7.1%
CEO 임기6yrs
CEO 소유권0.2%
경영진 평균 재임 기간5.5yrs
이사회 평균 재임 기간4.6yrs

최근 관리 업데이트

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Nov 03
IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Sep 28
Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Sep 16

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27
We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

IVERIC bio EPS misses by $0.05

Nov 02

CEO 보상 분석

Glenn Sblendorio 의 보수는 IVERIC bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2023n/an/a

-US$223m

Dec 31 2022US$10mUS$700k

-US$185m

Sep 30 2022n/an/a

-US$159m

Jun 30 2022n/an/a

-US$141m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$665k

-US$115m

Sep 30 2021n/an/a

-US$107m

Jun 30 2021n/an/a

-US$108m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$4mUS$640k

-US$85m

Sep 30 2020n/an/a

-US$77m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$2mUS$599k

-US$59m

Sep 30 2019n/an/a

US$63m

Jun 30 2019n/an/a

US$62m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$1mUS$625k

US$63m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

US$153m

Mar 31 2018n/an/a

US$144m

Dec 31 2017US$3mUS$560k

US$114m

Sep 30 2017n/an/a

US$57m

Jun 30 2017n/an/a

-US$192m

Mar 31 2017n/an/a

-US$200m

Dec 31 2016US$9mUS$373k

-US$193m

보상 대 시장: Glenn 의 총 보상 ($USD 9.82M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 7.81M ).

보상과 수익: 회사가 수익성이 없는 동안 Glenn 의 보상이 증가했습니다.

CEO

Glenn Sblendorio (67 yo)

6yrs

테뉴어

US$9,816,150

보상

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

리더십 팀

이름위치테뉴어보상소유권
Glenn Sblendorio
CEO & Director6yrsUS$9.82m0.17%
$ 9.6m
Pravin Dugel
President & Director2.2yrsUS$4.63m0.15%
$ 8.1m
David Carroll
Senior VP6.3yrsUS$2.68m0.032%
$ 1.8m
Keith Westby
Senior VP & COO6.5yrsUS$2.66m0.029%
$ 1.6m
Christopher Simms
Senior VP & Chief Commercial Officer1.9yrsUS$2.67m0.024%
$ 1.3m
Samir Patel
Co-Founder and Consultant16.5yrs데이터 없음데이터 없음
Xiao-Ping Dai
Chief Technical Officer2.5yrs데이터 없음데이터 없음
Kathy Galante
Senior VP of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Todd Anderman
Senior VP5.4yrs데이터 없음데이터 없음
Amy Sheehan
Senior VP & Chief Human Resources Officer5.5yrs데이터 없음데이터 없음
Evelyn Harrison
Senior VP & Chief Clinical Operations Officer7.5yrsUS$411.67k데이터 없음
Guangping Gao
Chief Strategist of Gene Therapy3.7yrs데이터 없음데이터 없음

5.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: ISEE 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Glenn Sblendorio
CEO & Director6.2yrsUS$9.82m0.17%
$ 9.6m
Pravin Dugel
President & Directorless than a yearUS$4.63m0.15%
$ 8.1m
Axel Bolte
Independent Director15.9yrsUS$354.59k0.016%
$ 882.5k
Adrienne Graves
Independent Chairman of the Board4.6yrsUS$398.34k0.016%
$ 882.5k
Mark Blumenkranz
Independent Director3yrsUS$354.59k0.023%
$ 1.3m
Carl Regillo
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Calvin Roberts
Independent Director4.5yrsUS$365.84k0.034%
$ 1.9m
Jane Pritchett Henderson
Independent Director5.5yrsUS$385.84k0.016%
$ 882.5k
Anat Lowenstein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jeffrey Heier
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Peter Kaiser
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Adnan Tufail
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

4.6yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: ISEE 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.